Aurinia Pharmaceuticals Inc AUPH
16.44
(0.16)
(0.96%)
as of 25 Sep
- Market cap
- $2.2B
- P/E
- 6.9×
Follow AUPH
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
19.05 | 7.35 | 6.56 | 7.10 |
P/S ratio |
5.48 | 7.57 | 6.58 | 7.09 | |
P/FCF ratio |
12.15 | 15.83 | 11.77 | 12.61 | |
P/Operating CF |
32.77 | 46.93 | 60.25 | 41.99 | |
P/B ratio |
3.98 | 3.69 | 3.46 | 3.59 | |
Price to Tangible BV |
4.02 | 3.71 | 3.48 | 3.61 | |
EV/Sales |
4.37 | 6.35 | 5.47 | 5.81 | |
EV/EBITDA |
11.66 | 13.42 | 10.93 | 11.30 | |
EV/Operating CF |
9.66 | 13.25 | 9.77 | 10.32 | |
EV/FCF |
9.68 | 13.27 | 9.79 | 10.33 | |
Quick Ratio |
5.02 | 4.69 | 4.94 | 4.85 | |
Current Ratio |
5.76 | 5.25 | 5.55 | 5.42 | |
Net Debt/EBITDA |
(8.33) | (10.47) | (7.11) | (8.88) | |
Debt/Assets |
10.56% | 6.96% | 6.65% | 5.55% | |
Debt/Equity |
0.15 | 0.09 | 0.08 | 0.07 | |
Asset Turnover |
0.49 | 0.43 | 0.49 | 0.48 | |
Operating CF/Net income |
1.41 | 0.22 | 0.95 | 1.41 | |
Capex/Depreciation |
(0.01) | (0.01) | (0.01) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.48% | 14.13% | 9.61% | 15.68% | |
Selling, General and Administrative Expense of Revenue |
35.64% | 37.94% | 28.35% | 28.25% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
8.06% | 8.72% | (1.11%) | 3.41% | |
Graham Net Nets |
0.19 | 0.15 | 0.17 | 0.16 | |
Graham Number |
6.02 | 14.53 | 14.77 | 15.94 | |
Earnings Yield |
5.25% | 13.61% | 15.25% | 14.08% | |
Free Cash Flow Yield |
8.23% | 6.32% | 8.49% | 7.93% | |
Revenue per Share |
0.56 | 0.57 | 0.59 | 0.64 | |
Operating CF per Share |
0.34 | 0.34 | 0.25 | 0.40 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.34 | 0.34 | 0.25 | 0.40 | |
Cash per Share |
2.67 | 2.96 | 2.86 | 3.41 | |
Shareholders Equity per Share |
2.78 | 4.33 | 4.29 | 4.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.78 | 4.33 | 4.29 | 4.73 | |
Free Cash Flow |
44.38 | 45.60 | 32.52 | 52.57 | |
Working Capital |
362.52 | 398.24 | 393.69 | 441.43 | |
Capital Expenditures |
(0.06) | (0.07) | (0.04) | 0.00 | |
Net Current Asset Value |
276.98 | 321.71 | 323.87 | 363.93 | |
EV/EBIT |
14.49 | 15.71 | 12.56 | 12.86 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
42.95% | 273.35% | 44.21% | 44.96% | |
Price to Operating Income |
18.18 | 18.73 | 15.11 | 15.70 | |
| Other line items | |||||
Average Receivables |
33.61 | 39.00 | 44.76 | 40.61 | |
Average Payables |
29.49 | 4.25 | 3.44 | 2.52 | |
Average Inventory |
41.75 | 42.46 | 46.30 | 45.83 | |
Average Assets |
538.44 | 651.12 | 614.42 | 647.41 | |
Average Common Equity |
376.89 | 479.40 | 458.91 | 475.08 |
Columns are period end dates